| 000 | 01727nam a2200373 i 4500 | ||
|---|---|---|---|
| 001 | 2133312 | ||
| 003 | StDuBDS | ||
| 005 | 20231010110710.0 | ||
| 006 | m|||||o||d|||||||| | ||
| 007 | cr ||||||||||| | ||
| 008 | 230117s2017 enka fob 001|0|eng|d | ||
| 020 |
_a9781910797389 (PDF ebook) : _cNo price |
||
| 020 |
_z9781910797334 (pbk.) : _cNo price |
||
| 020 | _z9781910797389 | ||
| 040 |
_aStDuBDS _beng _cStDuBDS _erda _epn |
||
| 060 | 4 | _aWE 258 | |
| 100 | 1 |
_aRamasamy, Karthik, _eauthor. |
|
| 245 | 1 | 0 |
_aMultiple myeloma and plasma cell dyscrasias / _h[e-book] |
| 250 | _aSecond edition. | ||
| 264 | 1 |
_aAbingdon, Oxford : _bHealth Press, _c2017. |
|
| 300 |
_a1 online resource (155 pages) : _billustrations (colour). |
||
| 490 | 1 | _aFast facts | |
| 500 | _aThis edition also issued in print: 2017. | ||
| 500 | _aPrevious edition: 2015. | ||
| 504 | _aIncludes bibliographical references and index. | ||
| 520 | 8 | _aOur understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. | |
| 521 | _aSpecialized. | ||
| 588 | _aDescription based on online resource; title from PDF title page (viewed on January 17, 2023). | ||
| 650 | 0 |
_aMultiple myeloma. _97046 |
|
| 650 | 2 |
_aMultiple Myeloma. _97046 |
|
| 700 | 1 |
_aLonial, Sagar, _eauthor. |
|
| 830 | 0 | _aFast facts. | |
| 856 | 4 | 0 |
_uhttps://app.kortext.com/Shibboleth.sso/Login?entityID=https://idp.eng.nhs.uk/openathens&target=https://app.kortext.com/borrow/2133312 _yEligible NHS OpenAthens account holders click here for access |
| 999 |
_c96882 _d96882 |
||